Your browser doesn't support javascript.
loading
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen, Tim; Frangou, Eleni; Oza, Bhavna; Ritchie, Alastair W S; Smith, Benjamin; Kaplan, Rick; Davis, Ian D; Stockler, Martin R; Albiges, Laurence; Escudier, Bernard; Larkin, James; Bex, Axel; Joniau, Steven; Hancock, Barry; Hermann, Gregers G; Bellmunt, Joaquim; Hodgkinson, Elizabeth; Stewart, Grant D; Barber, Jim; Brown, Janet; McMenemin, Rhona; Nathan, Paul; Pickering, Lisa M; Parmar, Mahesh K B; Meade, Angela.
Affiliation
  • Eisen T; Department of Oncology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, United Kingdom.
  • Frangou E; Medical Research Council Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, London, United Kingdom.
  • Oza B; Medical Research Council Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, London, United Kingdom.
  • Ritchie AWS; Medical Research Council Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, London, United Kingdom.
  • Smith B; Medical Research Council Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, London, United Kingdom.
  • Kaplan R; Medical Research Council Clinical Trials Unit at University College London (UCL), Institute of Clinical Trials and Methodology, London, United Kingdom.
  • Davis ID; Monash University and Eastern Health, Box Hill, Victoria, Australia.
  • Stockler MR; National Health and Medical Research Council Clinical Trials Centre, Central Clinical School, Department of Medicine, University of Sydney, Sydney, New South Wales, Australia.
  • Albiges L; Institut Gustave Roussy, Villejuif, France.
  • Escudier B; Institut Gustave Roussy, Villejuif, France.
  • Larkin J; The Royal Marsden Hospital, London, United Kingdom.
  • Bex A; Royal Free London NHS Foundation Trust UCL, Division of Surgery and Interventional Science, London, United Kingdom.
  • Joniau S; Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Hancock B; Department of Development and Regeneration, Urogenital, Abdominal, and Plastic Surgery, University Hospitals Leuven, Leuven, Belgium.
  • Hermann GG; University of Sheffield, Academic Unit of Clinical Oncology, Weston Park Cancer Centre, Sheffield, United Kingdom.
  • Bellmunt J; Urology Research Unit, Department of Urology, Herlev/Gentofte Hospital, Herlev, Denmark.
  • Hodgkinson E; Beth Israel Deaconess Medical Center-IMIM Research Lab, Boston, MA.
  • Stewart GD; Pharmacy Department, Weston Park Hospital, Sheffield, United Kingdom.
  • Barber J; Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom.
  • Brown J; Velindre Cancer Centre, Cardiff, United Kingdom.
  • McMenemin R; Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom.
  • Nathan P; Institute of Cancer and Pathology, St James's University Hospital, University of Leeds, Leeds, United Kingdom.
  • Pickering LM; Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
  • Parmar MKB; Mount Vernon Cancer Centre, Northwood, United Kingdom.
  • Meade A; The Royal Marsden Hospital, London, United Kingdom.
J Clin Oncol ; 38(34): 4064-4075, 2020 12 01.
Article in En | MEDLINE | ID: mdl-33052759
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Aromoterapia Main subject: Carcinoma, Renal Cell / Sorafenib / Kidney Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Language: En Journal: J Clin Oncol Year: 2020 Type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Aromoterapia Main subject: Carcinoma, Renal Cell / Sorafenib / Kidney Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Language: En Journal: J Clin Oncol Year: 2020 Type: Article Affiliation country: United kingdom